Interesting MRNA Put And Call Options For November 28th

Financial analysis highlights two options strategies for Moderna (MRNA), currently trading at $27.59. Selling a $26.00 strike put for a $1.53 premium offers an effective entry price of $24.47 or a 42.92% annualized return if the option expires worthless. Alternatively, a covered call strategy involving selling a $32.00 strike call for $1.71 could yield a 22.18% return if shares are called away by November 28th, or a 45.21% annualized return if the option expires worthless, providing income on existing holdings. These strategies leverage MRNA's implied volatility for income generation or discounted share acquisition.

Analysis

The article details two options strategies for Moderna (MRNA), currently trading at $27.59, designed to either acquire shares at a discount or generate income. These strategies leverage the current options market dynamics, offering specific entry points and potential returns for investors.

For investors aiming to acquire MRNA shares below the current market price, selling a cash-secured put at the $26.00 strike for a $1.53 premium results in an effective cost basis of $24.47. This strike is approximately 6% out-of-the-money, with a 65% probability of expiring worthless, which would yield a 42.92% annualized return on the committed cash.

Alternatively, for existing MRNA shareholders, a covered call strategy involves selling a $32.00 strike call for $1.71. This strategy offers a potential total return of 22.18% if the shares are called away by November 28th, or a 45.21% annualized return if the option expires worthless, which has a 60% probability.

The implied volatility for these options, at 77% for the put and 88% for the call, significantly exceeds MRNA's trailing twelve-month actual volatility of 66%. This higher implied volatility contributes to the attractive premiums and annualized returns, reflecting a speculative tone in the options market for MRNA.

Key Decisions for Investors

• Investors seeking MRNA exposure at a discount should consider selling the $26.00 strike put, targeting an effective entry price of $24.47 or a 42.92% annualized return if the option expires worthless.
• Current MRNA holders can implement a covered call strategy by selling the $32.00 strike call, potentially yielding a 22.18% return if shares are called away or a 45.21% annualized return if the option expires worthless.
• Acknowledge that the attractive option premiums are partly driven by elevated implied volatility (77-88%) relative to MRNA's historical volatility (66%), indicating higher perceived future price uncertainty that could impact strategy outcomes.